Kornimate/medical-research-clean huggingface dataset:
bio-enhanced curcumin as an add-on treatment in maintaining remission of ulcerative colitis

Conditions: Ulcerative Colitis

Summary: inflammatory bowel disease, including ulcerative colitis, is thought to result from an imbalance of pro-inflammatory and anti-inflammatory factors. as such, the majority of treatment options are directed at attempting to control the chronic inflammation and prolonging remission of clinical symptoms. several studies have proven that curcumin has well-established anti-inflammatory properties. however, curcumin has poor bioavailability and prior studies have needed to use high concentrations in order to study the efficacy of the product. the investigators propose that a bio-enhanced preparation of curcumin will require a lower dosage to reach and affect its target tissue and will subsequently produce less adverse side effects.


Eligibility criteria:
inclusion criteria: * patients who have been in symptomatic remission from ulcerative colitis for at least 3 months. this is defined as a partial mayo index score of 0 or 1 * age 18 years and above * male or female * patients who are able and willing to follow the treatment given and record responses in survey form exclusion criteria: * patients who are currently experiencing symptomatic flares of mild or moderate ulcerative colitis, or have a partial mayo index score of 2 or greater * patients who have been taking azathioprine or mercaptopurine for \<12 weeks for the treatment of their ulcerative colitis * patients who are taking steroids, immunosuppressants, or biologic agents for the treatment of their ulcerative colitis * patients who have severe ulcerative colitis * patients who are noncompliant with medication or regular follow up visits * patients who are unable or unwilling to record their responses in survey form * patients with comorbid illnesses, including: diabetes mellitus, stage iii or above congestive heart failure, chronic pancreatitis, severe liver or renal disease * patients who have current gallstones or biliary dysfunction * patients with anemia (hemoglobin \<10), thrombocytopenia, abnormal lymphocyte counts, or coagulation abnormalities * patients with current sepsis or current ongoing infection, including c. difficile colitis or enteritis * patients with a history of malignancy * patients who are currently pregnant or nursing * patients who are current smokers
telerehabilitation robotics for upper limb rehabilitation after stroke

Conditions: Stroke

Summary: there has been an observed decrease in motor and functional ability and non-use of the impaired limb in chronic patients. this is due to the immediate drop in intensive daily therapy (5 days per week for 3 hours/day) that is usually provided during the inpatient (acute) phase upon discharge from the hospital. in this study, the investigators plan to address the low dosage of therapy in the post-acute discharge phase for stroke survivors.

current models of care in public healthcare institutions (phi) cannot provide daily or frequent access to rat without increasing burden and expenditure in direct healthcare resources. shifting from the existing hospital-based model of care towards a home-centered model based deploying portable rat, would ensure that patients can continue to receive intensive therapy after discharge and during the chronic phase of stroke. more recently, rat deploying table-top, portable, less complex, upper limb end effectors enable clinic-to-home transitions may offer decentralized therapy, minimally supervised by therapists as a potential means to bridge various gaps in access to rat such as scheduling, physical or social barriers, distances and hospital lockdowns related to viral pandemics. this study aims to explore the utilization, feasibility and acceptability using a multi-cluster deployment and adoption of a decentralised robot-aided telerehabilitation (ratr) clinical programme supported by ai-enabled platform, with remote monitoring by clinic therapists

Eligibility criteria:
inclusion criteria: 1. clinical stroke (ischaemic or haemorrhagic) confirmed by admitting doctors and ct, ct angiography or mri brain imaging. 2. age 21 to 90 years, both males and females. 3. at least \> 28 days post stroke. 4. upper limb motor impairment of fugl-myer motor assessment (fma) scale 10 to 60 5. has a stable home abode and a carer/ nok to supervise home based exercise. 6. ability to sit supported continuously for 60 minutes. 7. montreal cognitive assessment (moca) score \> 21/30 8. able to understand purpose of research and give consent. exclusion criteria: 1. non-stroke related causes of arm motor impairment. 2. medical conditions incompatible with research participation: uncontrolled medical illnesses (hypertension or diabetes, ischaemic heart disease, congestive heart failure, bronchial asthma, end stage renal/liver/heart/lung failure, unresolved cancers. 3. anticipated life expectancy of \< 6 months. 4. inability to tolerate sitting continuously for 60 minutes. 5. local factors potentially worsened by intensive robot-aided arm therapy and computer-based training: active seizures within 3 months, spasticity of modified ashworth scale grades \>2 skin wounds, shoulder, arm pain vas \> 5/10, active upper limb fractures, arthritis, fixed upper limb flexion contractures. 6. hemianesthesia of affected limb. 7. history of dementia, severe depression, agitation, or behavioural problems. 8. pregnancy or lactation in females 9. absence of reliable carer to provide supervision during home training
acute resistance exercise and hydrolyzed collagen supplementation

Conditions: Diet; Food; Nutrition

Summary: this study aimed to investigate the effect of different doses of hydrolyzed collagen (hc) with resistance exercise (re) on whole body collagen synthesis in middle-aged males and females.

this study aimed to investigate the effect of different doses of hydrolyzed collagen (hc) with resistance exercise (re) on whole body collagen synthesis in healthy middle-aged males and females. healthy middle-aged males and females ingested 0 grams, 15 grams or 30 grams hc with 50 milligrams vitamin c 1h prior to performing four sets' leg press re at 10-repetition maximum load, after which they rested for six hours. blood samples were collected throughout each trial to analyse procollagen type ⅰ n-terminal propeptide (pⅰnp, a biomarker of collagen synthesis) and β-isomerized c-terminal telopeptide of type i collagen (β-ctx, a biomarker of collagen breakdown) concentration, and the concentration of 18 amino acids that constitute collagen. this is the first study to investigate the combined effect of different doses hc with high-intensity re on whole body collagen synthesis in middle-aged men and women. if 30 grams hc intake with re does augment collagen synthesis more than re alone, this suggests that long-term hc intake with chronic re would be beneficial for tendon health, because collagen is the most abundant protein in tendon.

Eligibility criteria:
inclusion criteria: * at least 12 months experienced in resistance exercise (including weekly lower body exercise) * free from musculoskeletal injury exclusion criteria: * having a history of patellar tendon pathology * vegan * consumed nutritional supplements or medication purported to have beneficial effects on muscle-tendon properties (e.g. antioxidants, protein, etc.) * had a sustained a lower limb injury in the previous six months * smoker/vaper * having reached menopause (only for middle-aged female participants)

Keywords: hydrolyzed collagen resistance exercise collagen synthesis proline glycine
a pilot study investigating the effect of omalizumab (xolair) in work-related animal induced asthma

Conditions: Allergy Induced Asthma

Summary: management of animal induced occupational asthma is mainly avoidance, but this is not feasible for many occupations. treatment with avoidance and conventional treatment is also not always successful. omalizumab is fda approved for the treatment of allergic asthma and may be effective at reducing symptoms and disease progression in the animal handlers population.


Eligibility criteria:
inclusion criteria: 1. ages 18-65 2. occupation that involves close contact with animals 3. stable dose of ics for 30 days 4. skin test positive to one or more animals 5. evidence of asthma on spirometry 6. demonstrate pefr variability- exclusion criteria: 1. on allergen immunotherapy 2. on prohibited medications 3. unstable asthma 4. recent uri 5. known hypersensitivity to omalizumab-
submassive and massive pulmonary embolism treatment with ultrasound accelerated thrombolysis therapy

Conditions: Pulmonary Embolism; Acute Pulmonary Embolism; Sub-massive Pulmonary Embolism; Massive Pulmonary Embolism; Pulmonary Thromboembolism

Summary: the purpose of this study is to determine if the ekos ekosonic® endovascular device when used in conjunction with recombinant tissue plasminogen activator (t-pa) as a treatment for acute pe will decrease the ratio of right ventricle (rv) to left ventricle (lv) diameter within 48 =/- 6 hours in participants with massive or submassive pe.


Eligibility criteria:
inclusion criteria: * computed tomography (ct) evidence of proximal pe (filling defect in at least one main or segmental pulmonary artery) * pe symptom duration less than or equal to (\<=)14 days * informed consent can be obtained from participant or legally authorized representative (lar) * massive pe (syncope, systemic arterial hypotension, cardiogenic shock, or resuscitated cardiac arrest) or * submassive pe (rv diameter-to-lv diameter greater than or equal to \[\>=\] 0.9 on contrast-enhanced chest ct) exclusion criteria: * stroke or transient ischemic attack (tia), head trauma, or other active intracranial or intraspinal disease within one year * recent (within one month) or active bleeding from a major organ * hematocrit less than (\<) 30 percent (%) * platelets \< 100 thousand/microliter (mcl) * international normalized ratio (inr) greater than (\>) 3 * activated partial thromboplastin time (aptt) \>50 seconds on no anticoagulants * major surgery within seven days of screening for study enrollment * serum creatinine \>2 milligrams/deciliter (mg/dl) * clinician deems high-risk for catastrophic bleeding * history of heparin-induced thrombocytopenia (hit) * pregnancy * catheter-based pharmacomechanical treatment for pulmonary embolism within 3 days of study enrollment * systolic blood pressure less than 80 mm hg despite vasopressor or inotropic support * cardiac arrest (including pulseless electrical activity and asystole) requiring active cardiopulmonary resuscitation (cpr) * evidence of irreversible neurological compromise * life expectancy \<30 days * use of thrombolytics or glycoprotein iib/iiia antagonists within 3 days prior to inclusion in the study * previous enrollment in the seattle study

Keywords: fibrinolysis catheter directed fibrinolysis ultrasound accelerated fibrinolysis recombinant t-pa activase
treatment effects on platelet calcium in hypertensive and depressed patients

Conditions: Depression; Hypertension

Summary: this study aims to determine if treatment with an ssri antidepressant medication, paroxetine, is associated with cellular calcium response to serotonin, platelet serotonin receptors, and improvement in mood in depressed patients with or without hypertension. it is hypothesized that platelets of hypertensive patients with depressive symptomatology with be hyper-responsive to serotonin. additionally, treatment with an ssri antidepressant is expected to produce a down-regulation of the serotonin receptor with an associated reduction in platelet cytosolic calcium response as well as improved mood.


Eligibility criteria:
subjects for all study groups will be male and between the ages of 25 and 65 hypertension \& depression group: hypertension controlled with an ace-inhibitor anti-hypertensive; no co-morbid medical conditions known to influence psychological functioning or platelet calcium responses including uncontrolled diabetes, mi or cva within 6 months of enrollment, secondary hypertension; depression as diagnosed by structured interview and hdrs score of 18; no active participation in another clinical trial; no current suicidal/ homicidal ideation hypertension group: hypertension controlled with an ace-inhibitor anti-hypertensive; no co-morbid medical conditions known to influence psychological functioning or platelet calcium responses including uncontrolled diabetes, mi or cva within 6 months of enrollment, secondary hypertension; no active participation in another clinical trial; no current suicidal/ homicidal ideation depression group: no co-morbid medical conditions known to influence psychological functioning or platelet calcium responses including uncontrolled diabetes, mi or cva within 6 months of enrollment, secondary hypertension; depression as diagnosed by structured interview and hdrs score of 18; no active participation in another clinical trial; no current suicidal/ homicidal ideation

Keywords: serotonin, hypertension, depression
exenatide and basal insulins use in the real setting: an observational study in patients with type 2 diabetes

Conditions: Type 2 Diabetes Mellitus

Summary: although the efficacy and safety profile of exenatide has been well established, few data exist on the real world results of exenatide treatment in specific populations and clinical settings. this study is intended to fill this gap through observing and collecting prospective data from a population of italian patients initiating treatment with either exenatide or basal insulin formulations after failure to achieve glycemic control with oral antihyperglycemic agents (oha). observational studies represent noninterventional research; therefore, this study does not involve randomization of patients to particular comparator arms or therapies. the term "noninterventional" means that the healthcare providers decisions regarding the proper treatment and care of the patient are made in the course of normal clinical practice. patients enrolled in this study are enrolling for the collection of their data on observations made during normal clinical practice.


Eligibility criteria:
inclusion criteria: 1. are inadequately controlled with single or multiple oha as evidenced by an hba1c \> 7.0% 2. have presented during the routine course of care and, together with their physician, have decided to initiate treatment with either exenatide twice daily or conventional insulin therapy with basal insulin (insulin glargine, detemir, protaminated insulin lispro, protaminated human insulin) added to the existing treatment with oha 3. have not been treated with glp-1 receptor agonist for more than 7 consecutive days within 3 months before entering the study 4. have not been treated with insulins for more than 7 consecutive days within last 3 months or more than 3 months in the course of the disease 5. are not simultaneously participating in another study which includes an investigational drug or procedure at study entry 6. have been fully informed and given their written consent for use of their data

Keywords: diabetes; exenatide; byetta; basal insulin; amylin; lilly
efficacy and tolerability of two different administration routes with slitoneplus birch

Conditions: Allergy

Summary: multicentre phase ii trial, comparing two different administration routes of slitoneplus birch in regard to pharmacodynamic efficacy and tolerability.


Eligibility criteria:
inclusion criteria: * a history of birch pollen allergy * positive skin prick test to birch * positive specific ige to birch exclusion criteria: * uncontrolled or severe asthma (fev1\<70% of predicted value in spite of adequate pharmacologic treatment) * previous treatment by immunotherapy with birch or a cross-reactingtree pollen allergen within the previous 5 years * concomitant slit with any allergen
local anesthetics for pain reduction prior to iv line placement

Conditions: Pain; Local Anesthesia for Peripheral Intravenous Catheterization

Summary: the purpose of this study is to compare the pain level felt by patients when receiving placement of a peripheral intravenous catheter (iv line) following the administration of a local anesthetic. the local anesthetics tested will be lidocaine, buffered lidocaine, and bacteriostatic normal saline. lidocaine is commonly used as a premedication for reducing the pain upon insertion of peripheral iv lines. however, due to its acidic nature, the lidocaine itself may cause pain upon administration. to help counter this discomfort, pharmacies can "buffer" the lidocaine using sodium bicarbonate, which increases the ph to a neutral value, resulting in less pain. bacteriostatic normal saline has also been used for local anesthesia with peripheral iv placement, particularly in patients with a lidocaine allergy, as it contains benzyl alcohol which acts as a local anesthetic. there are minimal reports from the literature that directly compare patient reported pain of all three agents to one another, although studies do exist that have compared buffered lidocaine versus lidocaine and buffered lidocaine versus bacteriostatic normal saline. to address this comparison gap, the following research questions need to be asked: which anesthetic agent is the superior premedication for reducing the amount of pain upon administration of the local anesthetic itself and for the pain associated with the peripheral insertion of the catheter? the hypothesis of the investigators is that there is not a significant difference in the degree of pain scales between the anesthetic agents to justify the pharmacoeconomic costs associated with compounding buffered lidocaine. the primary outcome measured in this study will be the level of pain reported by the patient upon administration of the local anesthetic and upon insertion of the peripheral intravenous catheter. a secondary outcome includes a pharmacoeconomic analysis that will look specifically at the cost-savings of using one agent over the other and will take into account the daily time allocated to pharmacy technicians and pharmacists for compounding and verifying buffered lidocaine.


Eligibility criteria:
inclusion criteria: * males or females \> 18 y.o. * ability to speak, read, an/or understand english * ability to communicate a level of pain via the specified pain scale * a written order exists for an intravenous peripheral catheter insertion for the patient exclusion criteria: * lidocaine allergy * buffered lidocaine allergy * benzyl alcohol allergy * non-english speaking * non-responsive or unable to understand or report pain score (ex. intubated in the icu) * inability to place catheter
pre- and post-operative brain mri in carotid endarterectomy

Conditions: Carotid Artery Stenoses

Summary: patients undergoing carotid endarterectomy in the department of vascular surgery at oslo university hospital are consecutively included in this evaluation og pre- and postoperative brain mri.

patients undergoing surgery for carotid stenosis in our department are examined by brain mri before and after carotid surgery to evaluate the rationale for the mri. brain lesions on mri before and after carotid surgery are registered, and related to clinical findings. the purpose of the study is to evaluate whether brain mri in relation to carotid endarterectomy gives additional information to clinical findings, and to ct scan of the brain.

Eligibility criteria:
inclusion criteria: * indication for carotid surgery exclusion criteria: * contraindications to mri
estimation of benefit from regular versus leakage-related exchange of voice prosthesis in patients post laryngectomy.

Conditions: Laryngectomy; Voice; Prosthesis Failure

Summary: the tracheoesophageal voice with voice prosthesis is currently the mainstay of voice rehabilitation post laryngectomy. the primary surgical technique of tracheoesophageal fistula formation with insertion of prosthesis and quick and easy process of voice rehabilitation are main encouraging factors. however, the usage of the prosthesis relates to a significant number of complications rated from 10 to 60%. the most common reported complication is transprosthetic leakage that determines the need of device exchange. however in some patients occur more serious complications eg. periprosthetic leakage, granulation or atrophy of mucosa around the fistula, dislocation of prosthesis, that may require anti-inflammatory treatment, temporary nasogastric tube feeding or surgical procedure. the standard protocol is voice prosthesis exchange due to transprosthetic leakage. optionally the device could be replaced regularly to prevent both transprosthetic leakage and other complication occurrence. in the study we plan to compare the benefits from regular (each three month) versus leakage-related exchange of voice prosthesis post laryngectomy including the rate of complications, fistula colonization by candida species and patients feedback.


Eligibility criteria:
inclusion criteria: * patients post laryngectomy with primary insertion of voice prosthesis exclusion criteria: * patients post laryngopharyngectomy with digestive tract reconstruction with jejunum of free flap

Keywords: voice prosthesis, laryngectomy, complications
a multicenter study of nb-001 in the treatment of recurrent herpes labialis

Conditions: Recurrent Herpes Simplex Labialis

Summary: demonstrate the safety and efficacy of nb-001 in subjects with recurrent herpes labialis (rhl).

this is a randomized, double-blind, two arm, parallel-group, vehicle-controlled, multi-center study of nb-001. the study is designed to demonstrate the safety and efficacy of nb-001 in subjects with rhl. approximately 850 subjects who meet all eligibility criteria will be randomized in the study. subjects will begin treatment as soon as they experience the onset of cold sore symptoms. treatment will be applied 5 times daily, approximately 3-4 hours apart while awake. treatment will continue until the investigator assesses the primary lesion complex as healed or a maximum of 4 days. clinic visits will occur on a daily basis until the investigator determines that the primary lesion complex has healed or a maximum of 15 clinic visits. at daily clinic visits, the investigator will make efficacy assessments of the primary lesion complex; safety and tolerability assessments of nb-001 following topical administration will also be assessed daily. subjects will make daily assessments of therapy. at the end of study, the investigator will make a global assessment of therapy. the subject will make global assessments of therapy and social impact.

Eligibility criteria:
inclusion criteria: * a healthy man or woman 18 years of age or older. women who are pregnant, lactating or may become pregnant may (at the investigator's discretion) be included in the study. * have recurrent herpes labialis as defined by a history of three (3) or more cold sore recurrences on the lips and/or skin surrounding the lips in the previous 12 months; * have the majority of their cold sore recurrences proceeded by a well defined history of prodromal symptoms. exclusion criteria: * subjects with severe chronic illness * received (within the last 6 months) or receiving chemotherapy; * significant skin disease on the face * previously received herpes vaccine; * active alcohol or drug abuse; * prior randomization into any nanobio study; * known allergies to topical creams, ointments or other topical medications.